Placeholder

Fostering interactions among industry, investors, government, and academia

Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases

View Full Article »